2seventy bio, Inc.
TSVT
$3.10
$0.4516.98%
| Weiss Ratings | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.84 | |||
| Price History | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 61.46% | |||
| 30-Day Total Return | 21.57% | |||
| 60-Day Total Return | -14.36% | |||
| 90-Day Total Return | -51.94% | |||
| Year to Date Total Return | -66.63% | |||
| 1-Year Total Return | -78.55% | |||
| 2-Year Total Return | -90.72% | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -82.62% | |||
| 52-Week Low % Change | 72.64% | |||
| Price | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $15.25 | |||
| 52-Week Low Price | $1.54 | |||
| 52-Week Low Price (Date) | Nov 22, 2023 | |||
| 52-Week High Price (Date) | Feb 06, 2023 | |||
| Valuation | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | $134.16M | |||
| Enterprise Value | 110.03M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -3.91 | |||
| Earnings Per Share Growth | -59.03% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.93 | |||
| Price/Book (Q) | 0.44 | |||
| Enterprise Value/Revenue (TTM) | 0.75 | |||
| Price | $3.10 | |||
| Enterprise Value/EBITDA (TTM) | -0.63 | |||
| Enterprise Value/EBIT | -0.60 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 51.179M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 339 499 9300 | |||
| Address | 60 Binney Street Cambridge, MA 02142 | |||
| Website | www.2seventybio.com | |||
| Country | United States | |||
| Year Founded | 2021 | |||
| Profitability | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -126.11% | |||
| Profit Margin | -126.05% | |||
| Management Effectiveness | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -17.04% | |||
| Return on Equity | -- | |||
| Income Statement | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | $145.88M | |||
| Total Revenue (TTM) | $145.88M | |||
| Revenue Per Share | $2.85 | |||
| Gross Profit (TTM) | -$112.07M | |||
| EBITDA (TTM) | -$174.40M | |||
| EBIT (TTM) | -$183.98M | |||
| Net Income (TTM) | -$183.89M | |||
| Net Income Avl. to Common (TTM) | -$183.89M | |||
| Total Revenue Growth (Q YOY) | -10.25% | |||
| Earnings Growth (Q YOY) | -5.54% | |||
| EPS Diluted (TTM) | -$3.91 | |||
| EPS Diluted Growth (Q YOY) | 20.46% | |||
| Balance Sheet | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | $250.62M | |||
| Cash Per Share (Q) | $4.90 | |||
| Total Current Assets (Q) | $277.25M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | $306.42M | |||
| Current Ratio (Q) | 4.077 | |||
| Book Value Per Share (Q) | $6.05 | |||
| Total Assets (Q) | $640.81M | |||
| Total Current Liabilities (Q) | $68.01M | |||
| Total Debt (Q) | $260.16M | |||
| Total Liabilities (Q) | $334.38M | |||
| Total Common Equity (Q) | $306.42M | |||
| Cash Flow | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -$4.56M | |||
| Cash from Financing (TTM) | $127.37M | |||
| Net Change in Cash (TTM) | -$35.94M | |||
| Levered Free Cash Flow (TTM) | -$98.44M | |||
| Cash from Operations (TTM) | -$158.74M | |||
